Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 87

Results For "NFI"

1310 News Found

How nutrigenomics can help you plan an effective and healthy diet
Opinion | September 20, 2022

How nutrigenomics can help you plan an effective and healthy diet

Nutrigenomics is the study of how genes and diet (nutrients) interact. Gene variants (genetic differences) predict how an individual’s body will respond to certain nutrients.


We must bring logistics cost from 13% to single digit as soon as possible: Narendra Modi
Policy | September 19, 2022

We must bring logistics cost from 13% to single digit as soon as possible: Narendra Modi

The policy aspires to reduce cost of logistics in India to be comparable to global benchmarks by 2030


Philips highlights FetView cloud-based image sharing and reporting software for obstetrics and gynecology
Digitisation | September 16, 2022

Philips highlights FetView cloud-based image sharing and reporting software for obstetrics and gynecology

Philips FetView will offer real-time, off cart remote patient management with access to data from any ultrasound system


Cytel unlocks innovative clinical development expertise for APAC biopharma sector
Biotech | September 15, 2022

Cytel unlocks innovative clinical development expertise for APAC biopharma sector

Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.


Dr. Jaidev Rajpal appointed MD & CEO of Jubilant Generics
People | September 15, 2022

Dr. Jaidev Rajpal appointed MD & CEO of Jubilant Generics

He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets


Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda  for urothelial cancer
Clinical Trials | September 13, 2022

Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda for urothelial cancer

Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab


Tata Memorial Centre suggests low-cost intervention for breast cancer
News | September 13, 2022

Tata Memorial Centre suggests low-cost intervention for breast cancer

If implemented across the world, it has the capability to save over 100,000 lives annually


AIIA launches 6-week long Ayurveda Day 2022 Programme
News | September 13, 2022

AIIA launches 6-week long Ayurveda Day 2022 Programme

The programme will see participation from various ministries of the Government of India with the aim of 3Js – Jan Sandesh, Jan Bhagidari, and Jan Aandolan.


Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer
Clinical Trials | September 10, 2022

Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer

The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients


Dr. Reddy's Laboratories launches Lenalidomide Capsules in the U.S.
News | September 09, 2022

Dr. Reddy's Laboratories launches Lenalidomide Capsules in the U.S.

Celgene agreed to provide Dr. Reddy's with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S.